about
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national surveyAssessment of Type I Interferon Signaling in Pediatric Inflammatory Disease.Novel monogenic diseases causing human autoimmunity.Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy.Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling.Detection of interferon alpha protein reveals differential levels and cellular sources in disease.Brief Report: Blockade of TANK-Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)-Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells.Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition.[Nosocomial rotavirus gastroenteritis].Ethambutol-related impaired visual function in childrens less than 5 years of age treated for a mycobacterial infection: diagnosis and evolution.Effect of biologic treatments on growth in children with juvenile idiopathic arthritis.PW03-033 - SLC29A3 mutation: a new autoinflammatory condition.Mevalonate kinase deficiency: an early onset inflammatory bowel disease?Systemic onset Juvenile Idiopathic Arthritis (SoJIA): a monocentric study of 114 patients.PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis.Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiencyComplications liées au vaccin BCG SSI® dans un hôpital pédiatrique : à propos de 2 casDéterminisme des troubles nutritionnels et métaboliques : impact de l’environnement diabétique durant la gestationInhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technologyAnti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signallingCirculating Interferon-α Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et alPaediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort
P50
Q36183846-323E566C-E791-4672-BE14-A0E1B35A44A5Q36923083-FDC8755D-D940-420C-AD33-CDF284762AC6Q37666293-52940341-4650-4B39-ACA7-ECCE17FCFA89Q38564442-E1AF154B-E042-4800-8891-3DE42598A742Q38730136-98792405-487E-4A56-81F5-E160D34CE551Q39021414-E2D22F6F-EFE1-4CDA-975D-9325E0FD93A0Q40237578-33646F57-8278-4B10-B7FF-198A0353FC13Q40243822-FCC37125-0E5E-4AAD-B065-288ECB608A8FQ40253289-D8AAB725-0539-4907-A17A-D324DE8A97F2Q40480081-9FDEFA39-EDB9-4FDB-B6B7-33C11EEAE0B0Q41435838-A34917E3-34B0-4BD6-BF27-B85ADD98EC3CQ43758730-C3AC01D3-7356-4FA6-814F-3FF0650738F7Q46052320-210A0DD1-EA82-4586-844D-7912C80B6DB6Q50276197-76705026-5D7A-4333-AD38-3B6E335A4D01Q55321353-71816BC8-D9BB-4202-A35A-3F5116BC7964Q55527753-302512D3-CA36-451B-B0D1-2A6014C09D8BQ59353949-4D2B25EF-7C68-4F99-ACA9-386BA0E72F33Q61960507-5849F8BB-A209-48DA-A8F9-25970064B1F8Q61960509-1EEB66F1-C788-400A-82C4-C3383D4A956FQ91006964-8CCC3F5C-0E3E-40E7-A6B3-7B3242673F99Q91394788-CFEBC8A5-7C74-4011-83F2-E893570F5EA2Q93121108-830697E0-8C26-46DE-AD27-8CE5AC40FD68Q96302066-02C9E398-A1DD-4485-ACAE-040ACA78D1B3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Isabelle Melki
@ast
Isabelle Melki
@en
Isabelle Melki
@es
Isabelle Melki
@sl
type
label
Isabelle Melki
@ast
Isabelle Melki
@en
Isabelle Melki
@es
Isabelle Melki
@sl
prefLabel
Isabelle Melki
@ast
Isabelle Melki
@en
Isabelle Melki
@es
Isabelle Melki
@sl
P214
P106
P21
P214
P31
P496
0000-0002-8057-333X
P734
P735
P7859
viaf-313541932